For other tumor types, such as breast or colon cancer, where the overexpression of TLR4 is frequently associated with a negative prognosis, the development of TLR4-inhibiting strategies targeting its co-receptor protein MD-2 could hold therapeutic promise [110,113,140,141]. This evidence concerns the gene TLR4 and neoplasm.